NasdaqGM - Nasdaq Real Time Price • USD
Nurix Therapeutics, Inc. (NRIX)
As of 11:29 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (May 2024) | Next Qtr. (Aug 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 11 | 11 |
| Avg. Estimate | -0.64 | -0.72 | -2.86 | -3.11 |
| Low Estimate | -0.89 | -0.86 | -3.53 | -4.93 |
| High Estimate | -0.47 | -0.61 | -2.44 | -2.44 |
| Year Ago EPS | -0.45 | -0.68 | -2.65 | -2.86 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (May 2024) | Next Qtr. (Aug 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 10 | 10 |
| Avg. Estimate | 22.89M | 17.74M | 72.95M | 67.65M |
| Low Estimate | 13.5M | 13.5M | 57.09M | 33.35M |
| High Estimate | 32.5M | 20M | 89.08M | 90M |
| Year Ago Sales | -- | -- | 76.99M | 72.95M |
| Sales Growth (year/est) | -- | -- | -5.20% | -7.30% |
Earnings History
| CURRENCY IN USD | 5/31/2023 | 8/31/2023 | 11/30/2023 | 2/29/2024 |
|---|---|---|---|---|
| EPS Est. | -0.56 | -0.76 | -0.57 | -0.8 |
| EPS Actual | -0.45 | -0.68 | -0.77 | -0.76 |
| Difference | 0.11 | 0.08 | -0.2 | 0.04 |
| Surprise % | 19.60% | 10.50% | -35.10% | 5.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (May 2024) | Next Qtr. (Aug 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.64 | -0.72 | -2.86 | -3.11 |
| 7 Days Ago | -0.67 | -0.74 | -2.91 | -3.17 |
| 30 Days Ago | -0.67 | -0.74 | -2.91 | -3.17 |
| 60 Days Ago | -0.83 | -0.8 | -3.13 | -3.11 |
| 90 Days Ago | -0.86 | -0.83 | -3.21 | -3.07 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (May 2024) | Next Qtr. (Aug 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | NRIX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -42.20% | -- | -- | 8.00% |
| Next Qtr. | -5.90% | -- | -- | 12.40% |
| Current Year | -7.90% | -- | -- | 5.60% |
| Next Year | -8.70% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Stifel: Buy to Buy | 5/15/2024 |
| Reiterates | Needham: Buy to Buy | 5/14/2024 |
| Initiated | Stephens & Co.: Overweight | 5/14/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 4/11/2024 |
| Maintains | Baird: Outperform to Outperform | 4/11/2024 |
| Reiterates | Needham: Buy to Buy | 4/11/2024 |
Related Tickers
KYMR Kymera Therapeutics, Inc.
36.53
+4.52%
IMTX Immatics N.V.
10.71
-2.28%
ARVN Arvinas, Inc.
32.68
-0.02%
DYN Dyne Therapeutics, Inc.
33.95
+22.65%
ITOS iTeos Therapeutics, Inc.
17.86
-1.05%
RVMD Revolution Medicines, Inc.
39.67
+0.66%
AKRO Akero Therapeutics, Inc.
19.91
-0.05%
RLAY Relay Therapeutics, Inc.
6.47
-2.64%
ORIC ORIC Pharmaceuticals, Inc.
9.04
-1.31%
DNLI Denali Therapeutics Inc.
20.46
-0.24%